Purpose of Review Breast cancer treatment continues to inhibitors in breast cancers are encouraging in patients with evolve as targeted therapeutic strategies are developed for germline deleterious BRCA1/2 mutations, continued work is the various molecular subtypes of breast cancer. The PARP needed to elucidate their utility beyond the BRCA1/2-mutated inhibitors represent a novel targeted therapy for tumors with population as has been possible in ovarian cancer. defective homologous recombination DNA repair. These Additionally, defining the ideal population and setting for agents may become standard new treatment options for pa- combination treatment remains a challenge and has been lim- tients harboring BRCA1/2 mutations and show promise in ited by synergistic toxicities. BRCA1/2 wild-type patients with triple-negative breast can- cers, which are treated predominantly with traditional cytotox- . . Keywords PARP inhibitors Breast cancer treatment ic chemotherapy. This review will discuss the results of clin- . . Targeted therapeutic strategies BRCA1/2 mutations Breast ical trials of these agents in breast cancer as well as important cancer ongoing and anticipated trials. Recent Findings Recent reports support the use of olaparib monotherapy in BRCA1/2-mutated metastatic cancer. Results of PARP inhibitor combinations with chemotherapy Introduction have been mixed. The addition of veliparib failed to
Current Breast Cancer Reports – Springer Journals
Published: Jul 28, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera